Cerebral perfusion imaging is a surrogate marker of Alzheimer’s disease progression in Down syndrome

Takeaway

  • Elevated amyloid burden in people with Down Syndrome is linked to reduced cerebral perfusion.

Why this matters

    Current methods to assess preclinical changes in Alzheimer’s disease in people with Down syndrome can be too burdensome and overwhelming for people with intellectual disabilities and cognitive impairment. These novel findings demonstrate the potential utility of perfusion imaging as a viable, less invasive surrogate marker of Alzheimer’s disease progression in this vulnerable population with Down syndrome.